Literature DB >> 35221481

Linagliptin-Induced Arthralgia.

Stefanie C Nigro1, Jennifer D Goldman2.   

Abstract

Entities:  

Year:  2022        PMID： 35221481      PMCID： PMC8865796          DOI： 10.2337/cd20-0110

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  13 in total

Review 1.  Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.

Authors:  P Men; N He; C Song; S Zhai
Journal:  Diabetes Metab       Date:  2017-08-01       Impact factor: 6.041

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 3.  Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.

Authors:  Annamaria Mascolo; Concetta Rafaniello; Liberata Sportiello; Maurizio Sessa; Daniela Cimmaruta; Francesco Rossi; Annalisa Capuano
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

4.  Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.

Authors:  Antonios Douros; Devin Abrahami; Hui Yin; Oriana Hoi Yun Yu; Christel Renoux; Marie Hudson; Laurent Azoulay
Journal:  Epidemiology       Date:  2018-11       Impact factor: 4.822

5.  Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.

Authors:  Caroline Ospelt; Joachim C Mertens; Astrid Jüngel; Fabia Brentano; Hanna Maciejewska-Rodriguez; Lars C Huber; Hossein Hemmatazad; Thomas Wüest; Alexander Knuth; Renate E Gay; Beat A Michel; Steffen Gay; Christoph Renner; Stefan Bauer
Journal:  Arthritis Rheum       Date:  2010-05

6.  Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.

Authors:  Chen-Yu Wang; Shau-Huai Fu; Rong-Sen Yang; Fei-Yuan Hsiao
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-06       Impact factor: 2.890

7.  Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.

Authors:  Wen-Hsuan Hou; Kai-Cheng Chang; Chung-Yi Li; Huang-Tz Ou
Journal:  Pain       Date:  2016-09       Impact factor: 6.961

Review 8.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

9.  DPP-4 INHIBITORS INCREASE THE INCIDENCE OF ARTHRITIS/ARTHRALGIA BUT DO NOT AFFECT AUTOIMMUNITY.

Authors:  Z A Sayiner; B Okyar; B Kısacık; E Akarsu; M Özkaya; M Araz
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

10.  Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus.

Authors:  Pragya Rai; Nilanjana Dwibedi; Mazhgan Rowneki; Drew A Helmer; Usha Sambamoorthi
Journal:  Am Health Drug Benefits       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.